Journal of Clinical Endocrinology & Metabolism, Vol 66, 552-556, Copyright © 1988 by Endocrine Society

ARTICLES

Stimulation of ovarian follicular maturation with pure follicle- stimulating hormone in women with gonadotropin deficiency

B Couzinet, N Lestrat, S Brailly, M Forest and G Schaison
Service d'Endocrinologie et des Maladies de la Reproduction, Hopital Bicetre, Kremlin Bicetre, France.

According to the 2-cell theory, ovarian steroidogenesis requires the coordinate action of both FSH and LH. To evaluate the relative importance of these hormones in follicular maturation, a randomized cross-over study was performed in 10 women with complete gonadotropin deficiency (absence of pulsatile LH secretion and no LH response to LHRH). Five women were treated with highly purified FSH (LH bioactivity, 0.09%) and 3 months later with human menopausal gonadotropin (hMG; LH bioactivity, 65%), each given for 10 days at a daily dose of 225 IU FSH, im. The sequence was reversed in the other 5 women. hCG (5000 IU) was administered im 24 h after the last injection of FSH or hMG. Plasma estradiol (E2), estrone (E1), androstenedione (A), testosterone, LH, and FSH concentrations and urinary LH and FSH were measured daily by RIA. Ultrasonography was performed during each treatment and 2 days after each hCG injection. After FSH treatment, mean plasma and urinary FSH levels increased, mean plasma LH did not change, and urinary LH increased slightly but not significantly from 91 +/- 32 (SE) to 164 +/- 55 mIU/24 h (10(-3) IU/24 h). After hMG treatment, mean plasma and urinary LH and FSH levels increased accordingly. The mean basal plasma E2 [11 +/- 1 pg/mL (40 +/- 4 pmol/L)] and E1 [14 +/- 4 pg/mL (52 +/- 15 pmol/L)] levels increased after FSH treatment to 207 +/- 69 pg/mL (760 +/- 253 pmol/L) and 82 +/- 21 pg/mL (303 +/- 78 pmol/L), respectively (P less than 0.01), but plasma A did not change. In response to hMG, the mean plasma E2, E1, A, and testosterone levels increased more than during FSH treatment. Ultrasonography revealed multiple preovulatory follicles (greater than or equal to 16 mm) in 2 women after hMG and 1 woman after FSH treatment; therefore, hCG was not administered. In 3 women given FSH, hCG did not induce ovulation. hCG induced ovulation in 8 women given hMG and in 6 women given FSH, based on ultrasonography and plasma progesterone levels. Thus, in the presence of profound gonadotropin deficiency pharmacological doses of FSH, with minute LH contamination, are capable of stimulating ovarian follicular maturation, underlining the key role of FSH in folliculogenesis.

This article has been cited by other articles:

				J. Balasch, F. Fabregues, J. Penarrubia, F. Carmona, R. Casamitjana, M. Creus, D. Manau, G. Casals, and J. A. Vanrell Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH Hum. Reprod., July 1, 2006; 21(7): 1884 - 1893. [Abstract] [Full Text] [PDF]

				B. Tarlatzis, E. Tavmergen, M. Szamatowicz, A. Barash, A. Amit, E. Levitas, and Z. Shoham The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study Hum. Reprod., January 1, 2006; 21(1): 90 - 94. [Abstract] [Full Text] [PDF]

				J.N. Hugues, J. Soussis, I. Calderon, J. Balasch, R.A. Anderson, A. Romeu, and on behalf of the Recombinant LH Study Group Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study Hum. Reprod., March 1, 2005; 20(3): 629 - 635. [Abstract] [Full Text] [PDF]

				E. Loumaye, P. Engrand, Z. Shoham, S. G. Hillier, D. T. Baird, and on behalf of the Recombinant LH Study Group Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation Hum. Reprod., February 1, 2003; 18(2): 314 - 322. [Abstract] [Full Text] [PDF]

				V. Garcia-Campayo and I. Boime Independent Activities of FSH and LH Structurally Confined in a Single Polypeptide: Selective Modification of the Relative Potencies of the Hormones Endocrinology, December 1, 2001; 142(12): 5203 - 5211. [Abstract] [Full Text] [PDF]

				S. Burgues The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain Hum. Reprod., December 1, 2001; 16(12): 2525 - 2532. [Abstract] [Full Text] [PDF]

				G. De Placido, A. Mollo, C. Alviggi, I. Strina, M. T. Varricchio, A. Ranieri, N. Colacurci, A. Tolino, and M. Wilding Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH Hum. Reprod., September 1, 2001; 16(9): 1875 - 1879. [Abstract] [Full Text] [PDF]

				S. F. Palter, A. B. Tavares, A. Hourvitz, J. D. Veldhuis, and E. Y. Adashi Are Estrogens of Import to Primate/Human Ovarian Folliculogenesis? Endocr. Rev., June 1, 2001; 22(3): 389 - 424. [Abstract] [Full Text] [PDF]

				J. Balasch, F. Fabregues, M. Creus, B. Puerto, J. Penarrubia, and J. A. Vanrell Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens Hum. Reprod., April 1, 2001; 16(4): 652 - 656. [Abstract] [Full Text] [PDF]

				G. Ricci, G. Tamaro, R. Simeone, E. Giolo, G. Nucera, F. De Seta, and S. Guaschino Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH Hum. Reprod., March 1, 2001; 16(3): 449 - 456. [Abstract] [Full Text] [PDF]

				J. Young, B. Couzinet, P. Chanson, S. Brailly, E. Loumaye, and G. Schaison Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3239 - 3244. [Abstract] [Full Text]

				R. Fleming, P. Rehka, N. Deshpande, M.E. Jamieson, R.W.S. Yates, and H. Lyall Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH Hum. Reprod., July 1, 2000; 15(7): 1440 - 1445. [Abstract] [Full Text] [PDF]

				S. B. Seminara, J. E. Hall, A. E. Taylor, W. F. Crowley Jr., and K. A. Martin The Reproductive Endocrine Associates of the Massachusetts General Hospital: Fifteen Years of Integrated Clinical Practice and Investigation J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1912 - 1918. [Full Text]

				O.H. Develioglu, B. Cox, J.P. Toner, S. Oehninger, and S.J. Muasher The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone* Hum. Reprod., May 1, 1999; 14(5): 1168 - 1174. [Abstract] [Full Text] [PDF]

				T. E. R. H. L. S. Group Recombinant Human Luteinizing Hormone (LH) to Support Recombinant Human Follicle-Stimulating Hormone (FSH)-Induced Follicular Development in LH- and FSH-Deficient Anovulatory Women: A Dose-Finding Study J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1507 - 1514. [Abstract] [Full Text]

				B. C. J. M. Fauser and A. M. van Heusden Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences Endocr. Rev., February 1, 1997; 18(1): 71 - 106. [Abstract] [Full Text]